{"id":"pemetrexed-disodium-heptahydrate","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Myelosuppression (neutropenia, anemia, thrombocytopenia)"},{"rate":"20-30","effect":"Nausea and vomiting"},{"rate":"15-25","effect":"Mucositis"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"20-30","effect":"Fatigue"},{"rate":"10-15","effect":"Elevated liver enzymes"},{"rate":"5-10","effect":"Renal toxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, key enzymes in the folate pathway required for purine and pyrimidine synthesis. By blocking these enzymes, it prevents cancer cells from synthesizing the nucleotides needed for DNA and RNA synthesis, leading to cell cycle arrest and apoptosis. The disodium heptahydrate formulation is the salt form used for intravenous administration.","oneSentence":"Pemetrexed is a multitargeted antifolate that inhibits multiple enzymes involved in nucleotide synthesis, disrupting DNA and RNA production in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:38.023Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer (nonsquamous histology)"},{"name":"Malignant pleural mesothelioma"},{"name":"Locally advanced or metastatic urothelial carcinoma"}]},"trialDetails":[{"nctId":"NCT01107626","phase":"PHASE3","title":"Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2010-10-25","conditions":"Lung Cancer","enrollment":1516}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["L-Glutamic acid","N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-","disodium salt","heptahydrate"],"phase":"phase_3","status":"active","brandName":"Pemetrexed Disodium Heptahydrate","genericName":"Pemetrexed Disodium Heptahydrate","companyName":"ECOG-ACRIN Cancer Research Group","companyId":"ecog-acrin-cancer-research-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pemetrexed is a multitargeted antifolate that inhibits multiple enzymes involved in nucleotide synthesis, disrupting DNA and RNA production in cancer cells. Used for Metastatic non-small cell lung cancer (nonsquamous histology), Malignant pleural mesothelioma, Locally advanced or metastatic urothelial carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}